Rivoglitazone

Rivoglitazone is an antidiabetic drug that belongs to the class of thiazolidinediones. It was developed by Eli Lilly and Company and primarily used in the treatment of Type 2 diabetes.

History

Rivoglitazone was developed in the late 1990s and early 2000s as a potential treatment for Type 2 diabetes. It was part of a new class of drugs known as thiazolidinediones, which were designed to increase the body's sensitivity to insulin.

Mechanism of Action

Rivoglitazone works by binding to the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. This binding increases the transcription of insulin-responsive genes, which leads to better glucose control in the body.

Clinical Trials

Rivoglitazone underwent several clinical trials to determine its efficacy and safety. These trials showed that the drug was effective in controlling blood glucose levels in patients with Type 2 diabetes. However, they also revealed potential side effects, including weight gain and an increased risk of heart failure.

Side Effects

The most common side effects of Rivoglitazone include weight gain, edema, and an increased risk of heart failure. Other potential side effects include anemia, increased risk of fractures, and a potential increase in the risk of bladder cancer.

Current Status

As of now, Rivoglitazone is not currently marketed. It was withdrawn from the market due to concerns about its side effects, particularly the increased risk of heart failure.

See Also

• Thiazolidinediones
• Type 2 diabetes
• Insulin
• Peroxisome proliferator-activated receptors
• Clinical trials